Initial management of intermediate-risk prostate cancer is evolving, with no clear recommendation ... 3.25-3.66), early T stage (T2c vs T1a through T2a: OR, 0.35; 95% CI, 0.32-0.38), treatment at an ...

Clinical stage T2b or T2c disease Patients previously diagnosed with low-risk (Gleason score 6, clinical stage T2a, and PSA 10 ng/mL) prostate cancer undergoing active surveillance who are re-biopsied ...

Disclosing a prostate cancer diagnosis can make some men vulnerable, but it has the potential to open up outlets for support.

Prostatitis is an inflamed prostate. Prostate cancer develops when cells in your prostate replicate too much and form a tumor ...

Scientists have discovered that a protein linked to prostate cancer is associated with more aggressive disease—it could be a ...

By tracking the changes in prostate cancer cells over time, researchers at the Johns Hopkins Kimmel Cancer Center have found that activation of the MYC gene -; a well-known cancer-causing gene -; sets ...

New research has shown that immunotherapy can be effective in treating prostate cancer in men who are selected based on the genetic characteristics of their tumors. In a recent study, it was found ...

New research has shown that immunotherapy can be effective in treating prostate cancer in men who are selected based on the genetic characteristics of their tumors.

The prostate is a small gland located in the male reproductive system that's essential for producing seminal fluid. When it's ...

My dad died of the "good kind" of cancer. He was 62 when he was diagnosed with prostate cancer, fought for 8 years and died at age 70. It was a brutal battle toward the end, and my family still ...

Prostate cancer is the second leading cause of death in men in the U.S., and 1 in 8 men will be diagnosed with prostate cancer during their lifetime, according to the American Cancer Society.